AR051803A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
AR051803A1
AR051803A1 ARP050105373A ARP050105373A AR051803A1 AR 051803 A1 AR051803 A1 AR 051803A1 AR P050105373 A ARP050105373 A AR P050105373A AR P050105373 A ARP050105373 A AR P050105373A AR 051803 A1 AR051803 A1 AR 051803A1
Authority
AR
Argentina
Prior art keywords
mono
organic compounds
glutamate
succinate
aspartate
Prior art date
Application number
ARP050105373A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR051803A1 publication Critical patent/AR051803A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composicion farmacéutica para la administracion parenteral de una sal de aspartato, por ejemplo mono- o di-aspartato, lactato, succinato, por ejemplo mono- o di-succinato, acetato, glutamato, por ejemplo, mono- o di-glutamato, o citrato de un análogo de somatostatina, y agua, la cual forma un sistema de deposito gelificante después de su inyeccion en contacto con el fluido corporal.
ARP050105373A 2004-12-22 2005-12-20 Compuestos organicos AR051803A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428151.5A GB0428151D0 (en) 2004-12-22 2004-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
AR051803A1 true AR051803A1 (es) 2007-02-07

Family

ID=34113101

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105373A AR051803A1 (es) 2004-12-22 2005-12-20 Compuestos organicos

Country Status (19)

Country Link
US (2) US20100029550A1 (es)
EP (1) EP1830806B1 (es)
JP (1) JP4977622B2 (es)
KR (1) KR101335757B1 (es)
CN (1) CN101072551B (es)
AR (1) AR051803A1 (es)
AU (1) AU2005318454B2 (es)
BR (1) BRPI0519209A2 (es)
CA (1) CA2585116C (es)
ES (1) ES2515097T3 (es)
GB (1) GB0428151D0 (es)
GT (1) GT200500358A (es)
MX (1) MX2007007572A (es)
PE (1) PE20060769A1 (es)
PL (1) PL1830806T3 (es)
PT (1) PT1830806E (es)
RU (1) RU2395274C2 (es)
TW (1) TW200637612A (es)
WO (1) WO2006066868A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US8937152B2 (en) 2007-12-03 2015-01-20 Italfarmaco Spa Non-selective somatostatin analogues
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
ES2677012T3 (es) 2010-01-13 2018-07-27 Ipsen Pharma S.A.S. Proceso para la preparación de composiciones farmacéuticas para la liberación sostenida de análogos de somatostatina
US8535544B2 (en) 2010-07-26 2013-09-17 International Business Machines Corporation Structure and method to form nanopore
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US11278507B2 (en) 2016-09-06 2022-03-22 Monell Chemical Senses Center Method of regulating immunity in the intestines
JP2020510011A (ja) * 2017-03-09 2020-04-02 コーセプト セラピューティクス， インコーポレイテッド カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
IL312678A (en) * 2021-11-22 2024-07-01 SpecGx LLC A sustained-release injectable medicinal compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3264693D1 (en) * 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
EP0949905B1 (en) 1996-12-20 2001-07-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1480618B1 (en) * 2002-03-04 2009-06-03 Ipsen Pharma Sustained release drug formulations containing a carrier peptide
GB0300095D0 (en) 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
ES2399651T3 (es) * 2008-07-08 2013-04-02 Novartis Ag Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena

Also Published As

Publication number Publication date
PE20060769A1 (es) 2006-09-28
KR101335757B1 (ko) 2013-12-02
RU2395274C2 (ru) 2010-07-27
MX2007007572A (es) 2007-07-24
PT1830806E (pt) 2014-11-24
JP2008524290A (ja) 2008-07-10
JP4977622B2 (ja) 2012-07-18
US20100029550A1 (en) 2010-02-04
CN101072551B (zh) 2013-04-24
EP1830806A2 (en) 2007-09-12
GB0428151D0 (en) 2005-01-26
GT200500358A (es) 2006-08-07
AU2005318454A1 (en) 2006-06-29
PL1830806T3 (pl) 2015-03-31
US20150038414A1 (en) 2015-02-05
EP1830806B1 (en) 2014-09-03
CN101072551A (zh) 2007-11-14
BRPI0519209A2 (pt) 2009-01-06
WO2006066868A3 (en) 2006-10-12
RU2007128101A (ru) 2009-01-27
AU2005318454B2 (en) 2009-08-20
CA2585116A1 (en) 2006-06-29
WO2006066868A2 (en) 2006-06-29
US9303067B2 (en) 2016-04-05
TW200637612A (en) 2006-11-01
CA2585116C (en) 2014-05-20
KR20070090942A (ko) 2007-09-06
ES2515097T3 (es) 2014-10-29

Similar Documents

Publication Publication Date Title
AR051803A1 (es) Compuestos organicos
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
UY27575A1 (es) Soluciones de metolixicam estables y muy concentradas para la inyección sin aguja
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
PE20130578A1 (es) Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE20080907A1 (es) Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
PE20090038A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos
RS54543B1 (en) Fast acting gastric acid secretion inhibitor
PE20210413A1 (es) Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad
BRPI0512649A (pt) artigos moldados sólidos contendo substáncias ativas para uso externo no combate a parasitas em animais
CR7967A (es) Sistema para prevenir la intrusion de agua salada
AR051664A1 (es) Agente contra la demodicosis
AR067048A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
WO2006095363A3 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts
AR047346A1 (es) Composicion farmaceutica de vinflunina para administracion parnteral, proceso de preparacion y uso de la misma
ECSP14013328A (es) Preparacion de liberacion sostenida
CL2011002444A1 (es) Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.
AR044983A1 (es) Solidos con capa de difusion modulada
AR066076A1 (es) Procedimiento para dosificar sistemas de liberacion de farmacos auto-emulsionantes
TH79952A (th) สารอินทรีย์
TH79952B (th) สารอินทรีย์
RU2006104442A (ru) Способ детоксикации организма в хирургии местнораспространенного гипернефроидного рака
DE602007008739D1 (de) Injizierbare pharmazeutische nimesulid-lösungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal